Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is among the 11 best long-term low-risk stocks to invest in, maintaining steady investor confidence after updating its clinical study. The company develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders, with U.S. approval for valbenazine (Ingrezza®) and ongoing trials for various conditions.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) terminated its Phase 2 study on NBI-921352 for SCN8A-DEE, a severe neurological disorder, due to lack of significant seizure reduction. Lead candidates include crinecerfont for congenital adrenal hyperplasia and NBI-1117568 for psychosis and cognitive disorders. Analysts like Truist and Morgan Stanley maintain a Buy rating with price target adjustments.

Despite setbacks, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shows strong growth potential with a projected EPS increase of 33.73% and a low beta of 0.25. However, other AI stocks may offer greater upside potential with less downside risk. Investors are advised to consider all options for maximizing returns in the current market.

Read more at Yahoo Finance: Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence